Friday, July 10, 2026

Drug profile · INN

crizanlizumab

crizanlizumab (ADAKVEO) is a p-selectin blocker.

EMA: unknown Blood and blood forming organs (B06) B06AX01
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — crizanlizumab
Class
Blood and blood forming organs (B06)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

crizanlizumab (ADAKVEO) is a p-selectin blocker.

Key facts

INN crizanlizumab
Brand ADAKVEO
Mechanism P-selectin blocker
Target P-selectin
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AX01

Mechanism of action

P-selectin blocker

Primary target: P-selectin

Approval history

Authority Status Date
EMA unknown

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is crizanlizumab?

crizanlizumab (ADAKVEO) is a p-selectin blocker.

What is the brand name for crizanlizumab?

ADAKVEO is a marketed brand name for crizanlizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.